Logo image of THTX

THERATECHNOLOGIES INC (THTX) Stock Price, Quote, News and Overview

NASDAQ:THTX - Nasdaq - CA88338H7040 - Common Stock - Currency: USD

3.16  -0.01 (-0.32%)

THTX Quote, Performance and Key Statistics

THERATECHNOLOGIES INC

NASDAQ:THTX (7/28/2025, 12:29:21 PM)

3.16

-0.01 (-0.32%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High3.2
52 Week Low1.12
Market Cap145.30M
Shares45.98M
Float34.58M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PE12.61
Earnings (Next)10-08 2025-10-08/bmo
IPO12-21 1993-12-21


THTX short term performance overview.The bars show the price performance of THTX in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 20 40 60 80

THTX long term performance overview.The bars show the price performance of THTX in the last 1, 2 and 3 years. 1 year 2 years 3 years 0 50 -50 100

The current stock price of THTX is 3.16 USD. In the past month the price increased by 35.47%. In the past year, price increased by 117.87%.

THERATECHNOLOGIES INC / THTX Daily stock chart

THTX Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 18.46 334.86B
AMGN AMGEN INC 14.63 163.31B
GILD GILEAD SCIENCES INC 14.72 141.69B
VRTX VERTEX PHARMACEUTICALS INC N/A 120.06B
REGN REGENERON PHARMACEUTICALS 12.81 61.28B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 42.94B
ARGX ARGENX SE - ADR 103.71 36.43B
ONC BEONE MEDICINES LTD-ADR 7.61 32.24B
BNTX BIONTECH SE-ADR N/A 27.32B
SMMT SUMMIT THERAPEUTICS INC N/A 20.69B
INSM INSMED INC N/A 19.62B
BIIB BIOGEN INC 8.25 19.14B

About THTX

Company Profile

THTX logo image Theratechnologies, Inc. is a pharmaceutical company, which engages in addressing medical needs of patients with Human Immunodeficiency Virus (HIV). The company is headquartered in Montreal, Quebec and currently employs 94 full-time employees. The firm is focused on the development and commercialization of therapies addressing unmet medical needs. The company markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The firm's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

Company Info

THERATECHNOLOGIES INC

2015 Peel Street, 11th Floor

MONTREAL QUEBEC H3A 1T8 CA

CEO: Paul Levesque

Employees: 103

THTX Company Website

THTX Investor Relations

Phone: 15143367800

THERATECHNOLOGIES INC / THTX FAQ

What is the stock price of THERATECHNOLOGIES INC today?

The current stock price of THTX is 3.16 USD. The price decreased by -0.32% in the last trading session.


What is the ticker symbol for THERATECHNOLOGIES INC stock?

The exchange symbol of THERATECHNOLOGIES INC is THTX and it is listed on the Nasdaq exchange.


On which exchange is THTX stock listed?

THTX stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for THERATECHNOLOGIES INC stock?

10 analysts have analysed THTX and the average price target is 4.11 USD. This implies a price increase of 29.93% is expected in the next year compared to the current price of 3.16. Check the THERATECHNOLOGIES INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is THERATECHNOLOGIES INC worth?

THERATECHNOLOGIES INC (THTX) has a market capitalization of 145.30M USD. This makes THTX a Micro Cap stock.


How many employees does THERATECHNOLOGIES INC have?

THERATECHNOLOGIES INC (THTX) currently has 103 employees.


What are the support and resistance levels for THERATECHNOLOGIES INC (THTX) stock?

THERATECHNOLOGIES INC (THTX) has a support level at 3.15 and a resistance level at 3.21. Check the full technical report for a detailed analysis of THTX support and resistance levels.


Is THERATECHNOLOGIES INC (THTX) expected to grow?

The Revenue of THERATECHNOLOGIES INC (THTX) is expected to decline by -1.97% in the next year. Check the estimates tab for more information on the THTX EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy THERATECHNOLOGIES INC (THTX) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does THERATECHNOLOGIES INC (THTX) stock pay dividends?

THTX does not pay a dividend.


When does THERATECHNOLOGIES INC (THTX) report earnings?

THERATECHNOLOGIES INC (THTX) will report earnings on 2025-10-08, before the market open.


What is the Price/Earnings (PE) ratio of THERATECHNOLOGIES INC (THTX)?

THERATECHNOLOGIES INC (THTX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.19).


What is the Short Interest ratio of THERATECHNOLOGIES INC (THTX) stock?

The outstanding short interest for THERATECHNOLOGIES INC (THTX) is 0.63% of its float. Check the ownership tab for more information on the THTX short interest.


THTX Technical Analysis

ChartMill assigns a technical rating of 10 / 10 to THTX. When comparing the yearly performance of all stocks, THTX is one of the better performing stocks in the market, outperforming 94.11% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

THTX Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to THTX. THTX has a medium profitability rating, but doesn't score so well on its financial health evaluation.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

THTX Financial Highlights

Over the last trailing twelve months THTX reported a non-GAAP Earnings per Share(EPS) of -0.19.


Industry RankSector Rank
PM (TTM) N/A
ROA -17.86%
ROE N/A
Debt/Equity N/A
Chartmill High Growth Momentum
EPS Q2Q%-550%
Sales Q2Q%-19.48%
EPS 1Y (TTM)0%
Revenue 1Y (TTM)2.19%

THTX Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 84% to THTX. The Buy consensus is the average rating of analysts ratings from 10 analysts.

For the next year, analysts expect an EPS growth of 147.68% and a revenue growth -1.97% for THTX


Ownership
Inst Owners24.06%
Ins Owners0.91%
Short Float %0.63%
Short Ratio0.41
Analysts
Analysts84
Price Target4.11 (30.06%)
EPS Next Y147.68%
Revenue Next Year-1.97%